Insiders Veracyte, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
19.57 ^USD	-3.79%		-1.31%	-28.86%

Apr. 15	Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating	MT
Feb. 26	Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating	MT

Veracyte, Inc. Announces Retirement of John L. Bishop, A Member of the Board of Directors	Feb. 13	CI
Veracyte, Inc. Appoints Phillip G. Febbo as Chief Scientific Officer and Chief Medical Officer, Effective 2, 2023	23-09-27	CI
Veracyte, Inc. Announces Resignation of Tina S. Nova as General Manager, Urological Cancers Effective September 4, 2023	23-08-08	CI
Insider Sell: Veracyte	23-07-24	MT
Insider Sell: Veracyte	23-07-20	MT
Insider Sell: Veracyte	23-06-21	MT
Insider Sell: Veracyte	23-04-18	MT
Eiger BioPharmaceuticals Names William Kachioff CFO, James Vollins General Counsel	23-04-13	MT
Insider Sell: Veracyte	23-03-17	MT
Insider Sell: Veracyte	23-03-02	MT
Insider Sell: Veracyte	23-01-18	MT
Insider Sell: Veracyte	23-01-12	MT
Veracyte, Inc. Announces Resignation of Giulia C. Kennedy as Global Chief Scientific Officer and Chief Medical Officer	22-12-14	CI
Insider Sell: Veracyte	22-12-05	MT
Veracyte, Inc. Names John Leite as Senior Vice President and General Manager of Pulmonology & Market Access	22-09-13	CI
Veracyte, Inc. Appoints Eliav Barr to Its Board of Directors	22-08-11	CI
Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year	22-06-27	BU
Insider Buy: Veracyte	22-06-13	MT
Veracyte, Inc. Appoints Annie Mcguire as Senior Vice President and General Counsel	22-02-28	CI
Veracyte, Inc Appoints Jonathan Wygant as Chief Accounting Officer	22-02-22	CI

No results for this search